CORV 1,43$ (-34%)

"U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp’s heart drug said on Friday they did not believe the benefits offered by the therapy outweighed its risks "

www.reuters.com/article/...o-not-outweigh-risks-idUSKBN1YA1IQ

Brinavess FDA Panel

www.benzinga.com/general/biotech/19/12/...avess-adcom-verdict

negatives FDA Panel

Soll Brivaness zugelassen werden (angesichts des Nutzen-Risiko-Verhältnisses)?

• 2x Ja
  
• 11x Nein
  

"The panel voted 11-2 against approving the drug, Brinavess, citing serious safety risks, including low blood pressure and irregular rhythm in the lower heart chambers, and deaths during the trials."

www.reuters.com/article/...in-fda-panel-backing-idUSL4N28K3U7

”

Correvio prüft strategische Alternativen incl. eines Verkaufs

"Correvio Pharma Corp. plans to explore strategic options to maximize stakeholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination or other strategic transaction involving the company or its assets."

Ich bin skeptisch angesichts der 18 Mio. $ Cash bei rund 11 Mio. $ Verlust in Q3/19 dürfte nach Q4 nicht mehr viel Cash übrig sein. MK liegt bei 23 Mio. $

www.reuters.com/article/...etback-shares-plunge-idUSKBN1YF1M7

www.fiercebiotech.com/biotech/...en-t-always-easy-sell-at-fda

FDA lehnt Zulassung von Brinavess ab

endpts.com/...-again-rejecting-battered-correvios-heart-drug/

Verstoß gegen die Nasdaq Regeln

www.newswire.ca/news-releases/...ed-securities-896520874.html